頁籤選單縮合
題 名 | 使用Tocilizumab引起反覆蜂窩性組織炎=Tocilizumab Induced Recurrent Cellulitis: A Case Report |
---|---|
作 者 | 鄭雅芳; 蔡慈貞; 羅淑芬; | 書刊名 | 藥學雜誌 |
卷 期 | 34:1=134 2018.03[民107.03] |
頁 次 | 頁103-108 |
分類號 | 415.72 |
關鍵詞 | 蜂窩性組織炎; 藥物不良反應; Tocilizumab; Rheumatoid arthritis; Cellulitis; Infection; |
語 文 | 中文(Chinese) |
中文摘要 | 近年來由於針對發炎反應中特定成分的生物製劑陸續被開發出來,革新了類風溼 性關節炎的治療,目前的生物製劑涵蓋不同的作用機制以達治療效果,但生物製劑的 治療可能增加感染風險。本案例是一名49歲女性病人,罹患類風濕性關節炎19年,在 使用 tocilizumab 治療三個月後發生右前臂的蜂窩性組織炎。抽血檢驗發現,白血球值 正常、嗜中性白血球及C反應蛋白數值稍微上升。在投予抗生素治療十二天後改善。 兩個月後醫師再次投予 tocilizumab,蜂窩性組織炎復發,以 Naranjo score 評估表評分 為6分,為極有可能相關之藥物不良反應。本案例報告的目的在提醒醫療人員使用生 物製劑時,必須對可能發生嚴重感染提高警覺。 |
英文摘要 | The treatment of rheumatoid arthritis has been revolutionized in recent years by the development of biologics targeting specific components of inflammation. The current biological agents consist of different mechanisms to achieve therapeutic effects. It has been clear that biological agents may be associated with an increased risk of infections. We report a 49-year-old female with 19-year history of rheumatoid arthritis. She received intravenous tocilizumab treatment and developed right hand and forearm cellulitis three months later. Laboratory examination showed a normal WBC count, and the neutrophil and CRP level were only slightly increased. Cellulitis resolved after antibiotics treatment for twelve days. Tocilizumab was resumed two months later and patient had recurrent cellulitis. The Naranjo score was 6 points and this adverse drug event can be classified as probable. This case report is to alert clinicians for infections while using biological agents. |
本系統中英文摘要資訊取自各篇刊載內容。